Nutriband NTRB 深 沪
等待开盘 11-06 09:30:00 美东时间
5.575
-0.505
-8.31%
华盛通- 最 高5.95
- 今 开5.95
- 成交量 3.51万股
- 最 低 5.28
- 昨 收 6.08
- 总市值 6776.79万
- 52周最高 9.1851
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 2.80
- 委 比 49.87%
- 总股本 1215.57万
- 历史最高 11.78
- 量 比 1.90
- 振 幅 11.02%
- 历史最低 1.53
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband raises $1.75M from warrant exercises to advance AVERSA Fentanyl
Nutriband (NTRB) received $1.75M from the exercise of 272,671 NTRBW warrants at $6.43 per share. The NTRBW warrants expired on September 30, with no extension, leaving the company with no remaining tr...
10-13 20:38
Nutriband Files U.S. Patent Application To Increase Protection For Its AVERSA Abuse Deterrent Transdermal Technology
This new patent application covers improved aversive formulations and coating application methods to enhance the abuse deterrent properties of Nutriband’s AVERSA™ transdermal technology and make it even more difficult to defeat. If this new patent is subsequently granted, it could significantly exte...
10-08 19:20
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
Nutriband files a non-provisional patent application to enhance intellectual property protection for its AVERSA™ transdermal abuse deterrent technology, targeting opioids and stimulants. The technology uses aversive agents to prevent abuse and accidental exposure, with existing patents in 46 countries. If granted, the new patent could extend protection until 2046, strengthening Nutriband's market position in abuse-deterrent transdermal products.
10-08 11:00
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband Inc. CEO Gareth Sheridan commemorated the company's five-year anniversary on Nasdaq, highlighting key milestones since its October 1, 2021, listing. Over the past five years, Nutriband advanced its lead product, AVERSA™ Fentanyl, from a feasibility concept to a commercially scalable product, while maintaining a focus on shareholder value and minimizing dilution. Key achievements include securing $8.7 million in gross proceeds, partnerin...
10-01 20:05
Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
Nutriband Inc. announced the appointment of Robert J. O'Neill, a former U.S. Navy SEAL and best-selling author, to its Advisory Board. O'Neill, known for his role in the operation that killed Osama bin Laden, brings extensive leadership and resilience expertise. He is also a vocal advocate for veterans' health, particularly psychedelic-assisted therapies, aligning with Nutriband's focus on developing abuse-deterrent fentanyl patches. O'Neill's ex...
09-25 12:00
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
Nutriband Inc. announced that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026, at 5PM ET, with no extension or repricing. Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds if fully exercised. Nutriband Inc. is focused on developing transdermal pharmaceutical products, includ...
09-22 12:00
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Nutriband Inc. has received a Notice of Publication from the USPTO for trademarks related to its abuse-deterrent fentanyl transdermal system. Once approved, the company plans to submit its commercial brand name to the FDA and other international regulators. The product, based on AVERSA™ technology, aims to prevent abuse and misuse of transdermal fentanyl. It has the potential to achieve peak annual US sales of $80 million to $200 million and addr...
09-08 13:00
Nutriband Q2 EPS $(0.07) Up From $(2.12) YoY, Sales $437.514K Down From $622.452K YoY
Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.07) per share. This is a 96.7 percent increase over losses of $(2.12) per share from the same period last year. The company reported $437.514 thousand in sales this quarter. This is a 29.71 percent decrease over sales of $622.452 thousand the ...
09-05 05:46
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Nutriband Inc. announced that its CEO, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit on August 26. The Summit, held in Sandy Springs, Georgia, highlights the state's leadership in life sciences innovation. Nutriband develops abuse-deterrent transdermal technology, with its AVERSA™ technology aiming to prevent drug abuse while ensuring patient access. The company is focused on creating transdermal pharmaceutical products, ...
08-13 11:00
Nutriband Q1 EPS $(0.10) Up From $(0.12) YoY, Sales $433.399K Down From $667.432K YoY
Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported $433.399 thousand in sales this quarter. This is a 35.06 percent decrease over sales of $667.432 thousand the...
06-12 05:16
